Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A glycoprotein IIb/IIIa inhibitor is an antiplatelet medicine that blocks receptors on the surface of activated platelets. These receptors normally bind fibrinogen and related proteins that link platelets together. Blocking this final common step of platelet aggregation reduces formation of platelet-rich blood clots. Examples include eptifibatide and tirofiban.
read more about glycoprotein iibiiia inhibitor ...Glycoprotein IIb/IIIa inhibitors are used in selected patients with acute coronary syndromes or during percutaneous coronary intervention. They can reduce thrombotic complications when rapid and potent platelet inhibition is needed. Current use is commonly limited to specific high-risk or procedural situations because other antiplatelet strategies are available. The decision depends on bleeding risk, kidney function, prior medicines, and findings during the procedure.
Platelet activation changes the glycoprotein IIb/IIIa receptor into a form that can bind fibrinogen. Fibrinogen then bridges neighboring platelets and helps build a platelet plug. Glycoprotein IIb/IIIa inhibitors occupy or block this receptor and prevent the bridging step. Their effect begins rapidly when the medicine is given intravenously.
These medicines are administered through a vein, commonly as an initial dose followed by an infusion. Dosing can depend on body weight, kidney function, and the clinical procedure. They are frequently used with aspirin, an anticoagulant, or another antiplatelet medicine under close supervision. Platelet counts, hemoglobin, bleeding, vascular access sites, and kidney function can require monitoring.
Bleeding is the main adverse effect and can occur at an access site, internally, or in another location. A rapid fall in platelet count can also occur and can be severe. Risk increases with other antithrombotic medicines, invasive procedures, older age, kidney impairment, or a history of bleeding. Active internal bleeding and certain recent bleeding events can make treatment inappropriate.
No. It is an antiplatelet medicine that prevents platelets from binding together. Anticoagulants interfere with proteins in the blood-clotting cascade.
They can provide rapid platelet inhibition when clot formation threatens blood flow during or around percutaneous coronary intervention. Their use is individualized because they also increase bleeding risk.
Some agents, including eptifibatide and tirofiban, are cleared partly through the kidneys and can require dose adjustment. Kidney function is reviewed before and during treatment.
Yes. A marked decrease in platelet count can occur, sometimes soon after administration. Platelet testing and prompt evaluation of unexpected bleeding are necessary.
Glycoprotein IIb/IIIa Inhibitors. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK554376/. Date Accessed August 5, 2026.
Eptifibatide. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK541066/. Date Accessed August 5, 2026.
Eptifibatide Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f46b76b-5c83-49b9-ada8-4ad5cf81a38c. Date Accessed August 5, 2026.
Tirofiban Hydrochloride Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa3ac570-f9f6-474c-a920-bd0cf03045ac. Date Accessed August 5, 2026.
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. American College of Cardiology. https://www.acc.org/guidelines/guidelines/2025/02/27/17/21/acute-coronary-syndromes-2025. Date Accessed August 5, 2026.